Table 2.
Tumor progression following administration of chemotherapeutics as single agent or in combination with carboplatin in A2780 ovarian cancer xenograft model.
| Administration Strategy a | Groups | Doses (mg/kg) | Tumor Progression b | |
|---|---|---|---|---|
| Size Increase (x-Fold Day-0) |
Significance c (p Values) |
|||
| Single Agents | Vehicle | 0 | 6.06 | na |
| Paclitaxel | 10 | 4.21 | ns | |
| Carboplatin | 40 | 4.21 | ns | |
| Docetaxel | 10 | 4.13 | ns | |
| TH1902 | 23 | 2.28 | 0.027 | |
| Combinations | Carboplatin + Paclitaxel | 40 + 10 | 4.27 | ns |
| Carboplatin + Docetaxel | 40 + 10 | 3.17 | 0.031 | |
| Carboplatin + TH1902 | 40 + 23 | 1.33 | 0.002 | |
a Single agents were administered bi-weekly, whereas combinations were administered once at start of study. b Tumor size progression at vehicle group endpoints compared to start of treatments (Day 0). Ratios > 1 indicate tumor progression c Significance between tumor progression of individual group vs. vehicle group endpoint using one-way ANOVA with Dunnett’s multiple comparisons test, na: not applicable, ns: not significant.